Aurinia Pharmaceuticals (AUPH) Receivables - Net (2015 - 2026)

Aurinia Pharmaceuticals (AUPH) has 12 years of Receivables - Net data on file, last reported at $49.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 21.87% year-over-year to $49.2 million; the trailing twelve-month figure through Mar 2026 stood at $49.2 million (up 21.87% YoY), and the FY2025 full-year result was $41.5 million, up 13.44% from the prior year.
• Receivables - Net for Q1 2026 stood at $49.2 million, up from $41.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $49.2 million in Q1 2026 and bottomed at $13.5 million in Q4 2022.
• The 5-year median for Receivables - Net is $30.7 million (2025), against an average of $30.8 million.
• The widest annual swing landed in 2022, when Receivables - Net jumped 1618.62%; it then fell 15.81% in 2025.
• A 5-year view of Receivables - Net shows it stood at $13.5 million in 2022, then jumped by 78.44% to $24.1 million in 2023, then soared by 51.7% to $36.5 million in 2024, then advanced by 13.44% to $41.5 million in 2025, then increased by 18.63% to $49.2 million in 2026.
• The last three Receivables - Net figures came in at $49.2 million (Q1 2026), $41.5 million (Q4 2025), and $30.7 million (Q3 2025), per Business Quant data.

Peer Comparison